入排依据:未发现恶性肿瘤人群证据。
摘要
摘要
Randomized-controlled Phase 2 trials are routinely skipped in oncology drug development in favor of directly going to confirmatory Phase 3 after signal-detection post dose-finding in Phase 1. With improved standard-of-care, this speed-oriented aggressive approach is not sustainable. It is time to apply the state-of-art adaptive 2-in-1 Phase 2/3 designs to mitigate the risk of costly Phase 3 failures and allow a study to choose the optimal path to success.
KM 提取结果
0 个 Figure · 0 个 KM 面板